TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23989814

Group type: EXPERIMENTAL
Intervention: Modified Ravitch repair (group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic repair using metal stabilizers (group B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic repair using absorbable stabilizers (group C)
Number of subjects: 31
Study: 21145834

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection
Number of subjects: 89

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 89

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 89
Study: 19298364

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v. (Group Ia, n=54)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (Group Ib, n=56)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v. (Group IIa, n=57)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (Group IIb, n=55)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v. (Group Ia and IIa)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (Group Ib and IIb)
Number of subjects: 222
Study: 17897485

Group type: EXPERIMENTAL
Intervention: dTpa
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: dTpa-IPV
Number of subjects: 460

Group type: COMPARATOR
Intervention: Td (control)
Number of subjects: 460
Study: 14991325

Group type: EXPERIMENTAL
Intervention: Hypoxic group (n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 11253854

Group type: EXPERIMENTAL
Intervention: SCVK 100, 300, or 400 microg administered depending on INR value
Number of subjects: 139

Group type: COMPARATOR
Intervention: Withholding warfarin
Number of subjects: 139
Study: 9554680

Group type: EXPERIMENTAL
Intervention: Active treatment with chlorthalidone and atenolol (or reserpine)
Number of subjects: 4736
Study: 7914260

Group type: EXPERIMENTAL
Intervention: Continued exclusive breastfeeding to 6 months (EBF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months with ad libitum nursing from 4-6 months (SF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months, with maintenance of baseline nursing frequency from 4-6 months (SF-M)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (EBF)
Number of subjects: 141
Study: 3056086

Group type: EXPERIMENTAL
Intervention: Music intervention via walkman
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thalamonal 1-2 ml i.m.
Number of subjects: 90

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 90
Study: 31782377

Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/d
Number of subjects: 71

Group type: COMPARATOR
Intervention: Choline intake of 480 mg/d
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Reproductive state (non-pregnant)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Reproductive state (pregnant)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Reproductive state (lactating)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Reproductive state (pregnant vs lactating)
Number of subjects: 71
Study: 28844293

Group type: EXPERIMENTAL
Intervention: Maropitant (1 mg kg−1, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (0.1 mL kg−1, n = 12)
Number of subjects: 24
Study: 25877989

Group type: EXPERIMENTAL
Intervention: MPH-MLR 20 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: MPH-MLR 40 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: MPH-MLR (various doses during open-label phase)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: MPH-MLR (various doses)
Number of subjects: 221
Study: 23522432

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet (initial carbohydrate intake 20 g/d, with a 10 g increase weekly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Energy-restricted (ER) diet (carbohydrate intake 156-205 g/d, ER to 5021 or 6276 kJ/d, 35% average energy reduction)
Number of subjects: 50
Study: 21406143

Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ProPex
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 50
Study: 19916807

Group type: EXPERIMENTAL
Intervention: Symptom severity measured with the Early Signs and Symptoms Scale
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress measured with the Hassles Scale
Number of subjects: 40
Study: 18254505

Group type: EXPERIMENTAL
Intervention: No Bite (a spray formulation with diethyl toluamide, 2 methyl 2,4 pentondiol and pthalic ester acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X‐pel (a petroleum jelly formulation containing diethyl toluamide (DEET) and dimethyl phthalate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zero Bite (a blend of microcrystalline waxes, mineral oils, natural flavours, Olibanum oil, Eucalyptus oil, Geranium oil, Citronella oil and Isopropyl myristrate)
Number of subjects: 0
Study: 14996104

Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg administered once weekly for 12 weeks
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Alefacept in course 1 and placebo in course 2
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study: 11300610

Group type: EXPERIMENTAL
Intervention: Clonidine 100-150 microg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline (without clonidine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of GFR changes between BG<10 mmol/L and BG>15 mmol/L
Number of subjects: 14
Study: 9043962

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg once a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8159601

Group type: EXPERIMENTAL
Intervention: Phenytoin sodium 250 mg (250 mg/5 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fosphenytoin 375 mg (375 mg/5 ml)
Number of subjects: 12
Study: 3063076

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 151

Group type: COMPARATOR
Intervention: Surgery (Discectomy)
Number of subjects: 151
Study: 31302249

Group type: EXPERIMENTAL
Intervention: GGA 400 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30625106

Group type: EXPERIMENTAL
Intervention: NT-proBNP monitoring (NPM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (NT-proBNP <1400 pg/ml)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Noncompliant patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sST2 concentration
Number of subjects: 100
Study: 28712212

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 154
Study: 25701345

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich blueberry drink
Number of subjects: 14

Group type: COMPARATOR
Intervention: Matched vehicle (control)
Number of subjects: 14
Study: 23194023

Group type: EXPERIMENTAL
Intervention: Soy isoflavones 60 mg and Lactobacillus sporogenes 1 billion spores
Number of subjects: 130

Group type: COMPARATOR
Intervention: Calcium and vitamin D₃
Number of subjects: 130
Study: 21092178

Group type: EXPERIMENTAL
Intervention: Philani intervention (home visits by Mentor Mothers for one year)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 788
Study: 18326331

Group type: EXPERIMENTAL
Intervention: Candesartan monotherapy (angiotensin receptor blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment with an ARB
Number of subjects: 0
Study: 17008704

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (fluorouracil 350 mg/m2/d during 5 days with leucovorin, 45 Gy in 25 fractions over 5 weeks)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (45 Gy in 25 fractions over 5 weeks)
Number of subjects: 733
Study: 12871405

Group type: EXPERIMENTAL
Intervention: Paracetamol 1500 mg daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Paracetamol 3000 mg daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10068849

Group type: EXPERIMENTAL
Intervention: Treatment for 7 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Heart failure patients (NYHA class III or IV)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Heart failure patients
Number of subjects: 98

Group type: COMPARATOR
Intervention: Healthy volunteers (N=26)
Number of subjects: 98
Study: 8595511

Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of protease inhibitors with reverse transcriptase inhibitors
Number of subjects: 0
Study: 1700203

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of enoximone orally
Number of subjects: 10
Study: 843178

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.5 mg/kg)
Number of subjects: 0
Study: 31347166

Group type: EXPERIMENTAL
Intervention: Pseudomonas luteola + Bacillus sp. (T2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pseudomonas luteola + Enterobacter sp. (T1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pseudomonas luteola + Acinetobacter sp. (T3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (T4)
Number of subjects: 100
Study: 27483990

Group type: EXPERIMENTAL
Intervention: DYN (dynamic warm-up: 4 × 4 crank-cycles)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ISO (isometric warm-up: 4 × 5-sec maximal voluntary contraction)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CON (control: rest)
Number of subjects: 6
Study: 25659029

Group type: EXPERIMENTAL
Intervention: Group A (six weekly doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group B (eight weekly doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group C (eight doses, two clustered doses over 3 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24528783

Group type: EXPERIMENTAL
Intervention: BASIC intervention (10,000 steps/day, no guidance on intensity), n=50
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ENHANCED intervention (10,000 steps/day and at least 30 minutes in moderate intensity), n=50
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group, n=20
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BASIC intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ENHANCED intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 22814766

Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique® (NET) - two 20-minute sessions
Number of subjects: 45

Group type: COMPARATOR
Intervention: Stretching instruction - two 20-minute sessions (active control group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention or instruction (passive control group)
Number of subjects: 45
Study: 19570307

Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dialysis without kidney transplant
Number of subjects: 72

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 72
Study: 18093312

Group type: EXPERIMENTAL
Intervention: Interactive 'pen and paper' intervention designed to increase intentions to perform three target behaviours (finding out what the patient knows, using explicit terminology, exploring what the diagnosis means).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persuasive communication targeting subjective norm.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural modelling and graded tasks targeting self-efficacy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persuasive communication targeting attitude towards explicit terminology.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural modelling targeting perceived behavioural control.
Number of subjects: 0
Study: 15083312

Group type: EXPERIMENTAL
Intervention: L. helveticus fermented milk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L. helveticus derived peptides
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control juice
Number of subjects: 20
Study: 12133516

Group type: EXPERIMENTAL
Intervention: 3 g/m2.d-1 of Ara-C administered by intravenous drip in 2 divided doses for two days (total dose 6 g/m2) + rhG-CSF at 300 microg.body(-1).d(-1) subcutaneously once a day until APBSC harvest.
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5 g/m2.d-1 of Ara-C administered by intravenous drip in 2 divided doses for two days (total dose 10 g/m2) + rhG-CSF at 300 microg.body(-1).d(-1) subcutaneously once a day until APBSC harvest.
Number of subjects: 22
Study: 9718254

Group type: EXPERIMENTAL
Intervention: lamotrigine (300 mg p.o.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: phenytoin (300 mg p.o.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: dihydrocodeine (90 mg p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7862843

Group type: EXPERIMENTAL
Intervention: Diazepam (0.18 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3434168

Group type: EXPERIMENTAL
Intervention: Single intercostal block with bupivacaine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Repeated intercostal block
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine infusions
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (single dose of intercostal bupivacaine)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 39
Study: 28591071

Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) steroid injection (0.5 mL of 0.5% bupivacaine mixed with 10 mg dexamethasone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Therapeutic thoracic medial branch block (MBB) (0.5 mL of 0.5% bupivacaine mixed with 10 mg dexamethasone)
Number of subjects: 40
Study: 27619779

Group type: EXPERIMENTAL
Intervention: 73.5 mg oxybutynin patch
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: 105 mg oxybutynin patch
Number of subjects: 579

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study: 24738786

Group type: EXPERIMENTAL
Intervention: Panasonic EW-DL90
Number of subjects: 84

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 84
Study: 22818117

Group type: EXPERIMENTAL
Intervention: Single Event Multilevel Surgery (SEMLS)
Number of subjects: 19
Study: 19937427

Group type: EXPERIMENTAL
Intervention: 360 microg MK-7 in the form of Natto capsules
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo capsules containing olive oil
Number of subjects: 334
Study: 18415823

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 487

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 487
Study: 19661446

Group type: EXPERIMENTAL
Intervention: 10 mM ketorolac
Number of subjects: 13

Group type: COMPARATOR
Intervention: 10 mM N(G)-nitro-l-arginine methyl ester (NOS-inhibited)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Combined NOS and COX inhibition
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (Ringer)
Number of subjects: 13
Study: 16400368

Group type: EXPERIMENTAL
Intervention: Structured Form (SF)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional Medical Record (TMR)
Number of subjects: 400
Study: 11596162

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oscillating positive expiratory pressure (OPEP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Postural drainage, percussion, and vibration (PDPV)
Number of subjects: 29
Study: 9470081

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD) with oral non-absorbable antibiotics (polymyxin E, tobramycin and amphotericin B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No administration (Control group)
Number of subjects: 100
Study: 8204282

Group type: EXPERIMENTAL
Intervention: Captopril therapy in addition to acetylsalicylic acid (ASA) and isosorbide dinitrate (ISDNI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) and isosorbide dinitrate (ISDNI)
Number of subjects: 0
Study: 3673207

Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell culture rabies vaccine (PCECV)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (HDCSV)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Intradermal (i.d.) vaccination with 0.1 ml
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Schedule of immunization on days 0, 28, and 56
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: PCECV
Number of subjects: 177
Study: 30878629

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 28228418

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28920356

Group type: EXPERIMENTAL
Intervention: Choudongning (CDN) capsule
Number of subjects: 588

Group type: COMPARATOR
Intervention: Tiapridal tablets
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 25072396

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15000
Study: 23112428

Group type: EXPERIMENTAL
Intervention: Case Based Teaching (CBT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Traditional Method of Teaching (TRD)
Number of subjects: 179
Study: 19885408

Group type: EXPERIMENTAL
Intervention: High-speed handpiece without coolant
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-speed handpiece with coolant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-speed polishing without coolant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-speed polishing with coolant
Number of subjects: 60
Study: 17565921

Group type: EXPERIMENTAL
Intervention: Intravenous conivaptan 20 mg loading dose (day 1) + 40 mg/d continuous infusion (days 1-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous conivaptan 20 mg loading dose (day 1) + 80 mg/d continuous infusion (days 1-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15500894

Group type: EXPERIMENTAL
Intervention: Single-dose brachytherapy (12 Gy)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Self-expanding metal stent placement
Number of subjects: 209
Study: 11549798

Group type: EXPERIMENTAL
Intervention: EE/CMA (Belara)
Number of subjects: 199

Group type: COMPARATOR
Intervention: EE/LNG (Microgynon)
Number of subjects: 199
Study: 10456135

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg daily (increased to 6 mg if no satisfactory response)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg daily (increased to 50 mg if necessary)
Number of subjects: 41
Study: 7524263

Group type: EXPERIMENTAL
Intervention: Intravenous, polyethyleneglycol‐treated, human immunoglobulin at 200 mg/kg per day for five consecutive days (group A)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Intravenous, polyethyleneglycol‐treated, human immunoglobulin at 400 mg/kg per day for five consecutive days (group B)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Freeze‐dried, sulfonated human immunoglobulin at 200 mg/kg per day for five consecutive days (group C)
Number of subjects: 451
Study: 3601609

Group type: EXPERIMENTAL
Intervention: Reading only
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Listening only
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Reading and listening
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (below average readers)
Number of subjects: 300
Study: 29265922

Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Number of subjects: 222

Group type: COMPARATOR
Intervention: Traditional face-to-face care
Number of subjects: 222
Study: 27259583

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (TCS) application via soak and smear (SS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical corticosteroid (TCS) application to dry skin
Number of subjects: 45
Study: 23927381

Group type: EXPERIMENTAL
Intervention: Supplemented drink containing soy isoflavones, lycopene, vitamin C, and vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsule containing fish oil (Control)
Number of subjects: 0
Study: 24438569

Group type: EXPERIMENTAL
Intervention: Complete denture with lingualized occlusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Complete denture with anatomic occlusion
Number of subjects: 70
Study: 20837284

Group type: COMPARATOR
Intervention: Enhanced usual care reminders (EUCR)
Number of subjects: 3547

Group type: EXPERIMENTAL
Intervention: Barriers plus positive consequences of getting mammograms (BarriConCall+)
Number of subjects: 3547

Group type: EXPERIMENTAL
Intervention: Barriers plus negative consequences of not getting mammograms (BarriConCall‐)
Number of subjects: 3547

Group type: EXPERIMENTAL
Intervention: Barriers only (BarriCall)
Number of subjects: 3547
Study: 17658632

Group type: EXPERIMENTAL
Intervention: Statins and fibrates (specific types not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrates (specific types not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins combined with gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins combined with fenofibrate, bezafibrate, or ciprofibrate
Number of subjects: 0
Study: 16386999

Group type: EXPERIMENTAL
Intervention: 1600 IU/day of vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11842026

Group type: EXPERIMENTAL
Intervention: 100% O(2) (hyperoxia)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5% CO(2) and 15% O(2) (hypoxic hypercapnia)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal air
Number of subjects: 6